Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD7594 + abediterol is an inhaled fixed-dose combination (FDC) therapy being developed by AstraZeneca for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The combination consists of AZD7594 (also known as velsecorat), a non-steroidal, potent, and selective modulator of the glucocorticoid receptor (SGRM), and abediterol, a novel long-acting beta-2 adrenergic receptor agonist (LABA). AZD7594 is designed to provide anti-inflammatory effects with a potentially reduced systemic side-effect profile compared to traditional inhaled corticosteroids, while abediterol provides sustained bronchodilation. The combination is intended for once-daily administration via a dry powder inhaler (DPI) to improve lung function and manage symptoms in patients with obstructive airway diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AZD7594 + abediterol.